Hi desrt, this was on the expert commentary part... Hope all is well.
Use of Telaprevir in Genotype 2 or 3 HCV—Not Likely
Mitchell L. Shiffman, MD
Posting Date: December 13, 2011
Director, Liver Institute of Virginia
Bon Secours Virginia Health System
Richmond and Newport News, Virginia
Telaprevir works very effectively against hepatitis C virus (HCV) genotype 1 infection, and a wealth of data support this fact.[1-5] By contrast, there are very few data about the efficacy of telaprevir in HCV genotypes 2 and 3, particularly in combination with peginterferon/ribavirin.
To shed light on this issue, Foster and colleagues conducted a randomized phase IIa study in patients chronically infected with HCV genotype 2 or 3 to determine whether the addition of telaprevir to peginterferon/ribavirin enhanced the rates of sustained virologic response (SVR). In total, 26 patients with HCV genotype 2 (23 were treated) and 26 patients with HCV genotype 3 infection were randomly assigned to receive 15 days of telaprevir, telaprevir plus peginterferon/ribavirin, or peginterferon/ribavirin, all followed by peginterferon/ribavirin for 22-24 weeks.
Unfortunately, the results of this study were somewhat disappointing. There was additive efficacy with telaprevir in patients with HCV genotype 2 infection. For example, the kinetics of virologic suppression occurred earlier and was deeper with the addition of telaprevir to peginterferon/ribavirin vs peginterferon/ribavirin alone (eg, median HCV RNA change at Day 3: -4.03 vs -2.04 log10 IU/mL; median HCV RNA change at Day 15: -5.51 vs -4.83 log10 IU/mL). All 5 patients who received telaprevir/peginterferon/ribavirin triple therapy attained SVR compared with 8 of 9 patients assigned to peginterferon/ribavirin control (100% vs 89%). One must recognize, however, that infection with HCV genotype 2 has the highest cure rate of all HCV genotypes when treated with peginterferon/ribavirin. Thus, despite having some antiviral activity against this type of HCV, the addition of telaprevir to peginterferon/ribavirin really has very little impact on overall SVR in this patient population.
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.